Home › Companies › VIRIDIAN THERAPEUTICS INC. › 2024-2025

VIRIDIAN THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and VIRIDIAN THERAPEUTICS INC.’s Form 8-K, filed 2025-06-24 (Item 5.07 on EDGAR). Page generated 02 October 2026.

9Reported items
199Asset managers
1,561Fund votes
2025-06-20Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VIRIDIAN THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by VIRIDIAN THERAPEUTICS INC.

These tallies are VIRIDIAN THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-24 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VIRIDIAN THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-20
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jeff Ajer	71,946,644	--	--	95,588	4,619,287	Majority: yes
Elect Director: Chris Cain, Ph.D.	68,841,891	--	--	3,200,341	4,619,287	Majority: yes
Elect Director: Sarah Gheuens, M.D., Ph.D.	55,346,802	--	--	16,695,430	4,619,287	Majority: yes
Proposal 2: Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:	76,059,006	577,139	25,374	--	--	Majority: yes
Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers:	56,046,366	15,957,526	38,340	--	4,619,287	Majority: yes
Proposal 4: Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including increasing the number of shares available for issuance thereunder by 8,000,000 shares:	35,322,725	35,076,902	1,642,605	--	4,619,287	Majority: yes
Proposal 5: Approval of the Viridian Therapeutics, Inc.	72,005,896	25,668	10,668	--	4,619,287	Majority: yes

Source: VIRIDIAN THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-24 — read the filing on EDGAR.

How asset managers voted at the VIRIDIAN THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 199 asset managers that disclosed a VIRIDIAN THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of VIRIDIAN THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%AGAINST 22%

FOR: 56,046,366AGAINST: 15,957,526

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers:”): 56,046,366 for, 15,957,526 against, per its Form 8-K filed 2025-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,589,427 outstanding shares: 69% for, 20% against (88% of the company cast a for/against vote).

The 197 asset managers below cast 80% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 80%AGAINST 20%

FOR: 79.6%AGAINST: 20.4%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	24,268,702	0	For
Commodore Capital LP	0	5,250,000	Against
Vanguard	4,640,718	709	For
VR Adviser, LLC	3,882,709	0	For
BlackRock	3,717,921	6,709	For
T. Rowe Price	3,669,244	0	For
Kynam Capital Management, LP	3,477,428	0	For
Fairmount Funds Management LLC	3,445,813	0	For
State Street	3,161,891	31,954	For
AllianceBernstein	0	2,779,157	Against
Deep Track Capital, LP	2,526,662	0	For
Novo Holdings A/S	2,327,640	0	For
Loomis Sayles	2,027,232	91,496	For
Paradigm Biocapital Advisors LP	0	2,095,079	Against
GEODE CAPITAL MANAGEMENT, LLC	1,726,192	0	For
MAVERICK CAPITAL LTD	1,698,673	0	For
Eversept Partners, LP	1,586,421	0	For
Victory Capital	0	1,312,528	Against
Charles Schwab	1,180,816	0	For
PICTET ASSET MANAGEMENT SA	0	1,128,441	Against
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	1,114,586	Against
Vivo Capital, LLC	982,576	0	For
Woodline Partners LP	813,376	0	For
5AM Venture Management, LLC	736,595	0	For
JPMorgan	434,709	0	For

Showing the 25 largest of 197 asset managers. See all 197 in the interactive database.

2. To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including increasing the number of shares available for issuance thereunder by 8,000,000 shares.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

50.2% Majority: yes · of votes cast

FOR 50.2%AGAINST 49.8%

FOR: 35,322,725AGAINST: 35,076,902

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including increasing the number of shares available for issuance thereunder by 8,000,000 share”): 35,322,725 for, 35,076,902 against, per its Form 8-K filed 2025-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,589,427 outstanding shares: 43% for, 43% against (86% of the company cast a for/against vote).

The 60 asset managers below cast 40% of the shares they voted on this item FOR (12,197,551 for, 18,355,536 against).

FOR 40%AGAINST 60%

FOR: 12,197,551 (39.9%)AGAINST: 18,355,536 (60.0%)ABSTAIN: 16,664 (0.1%)

Largest asset managers voting on “To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Pla” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Fidelity	23,887	12,237,162	0	Against
Vanguard	4,462,994	0	0	For
Kynam Capital Management, LP	3,477,428	0	0	For
BlackRock	1,711,951	0	0	For
T. Rowe Price	0	1,575,728	0	Against
AllianceBernstein	0	1,058,977	0	Against
State Street	2,547	891,151	0	Against
Loomis Sayles	784,032	0	0	For
Charles Schwab	581,864	0	0	For
Victory Capital	0	500,814	0	Against
Yiheng Capital Management, L.P.	278,786	0	0	For
Bridge Builder Trust	19,621	253,330	0	Against
Brighthouse	180,411	55,939	16,664	For
Brinker Capital Destinations Trust	0	230,461	0	Against
Principal	159	212,510	0	Against
Equitable	133,110	69,270	0	For
DRIEHAUS MUTUAL FUNDS	0	185,549	0	Against
TIAA	0	182,918	0	Against
JPMorgan	170,552	0	0	For
OPTIMUM FUND TRUST	0	131,578	0	Against
QUANTITATIVE MASTER SERIES LLC	128,358	0	0	For
American Century	0	122,726	0	Against
CARILLON SERIES TRUST	0	88,326	0	Against
AIG/SunAmerica	0	78,390	0	Against
Russell Investments	76,504	0	0	For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

3. TO APPROVE THE VIRIDIAN THERAPEUTICS, INC. 2025 EMPLOYEE STOCK PURCHASE PLAN.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 72,005,896AGAINST: 25,668

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Proposal 5: Approval of the Viridian Therapeutics, Inc.”): 72,005,896 for, 25,668 against, per its Form 8-K filed 2025-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,589,427 outstanding shares: 88% for, 0.1% against (88% of the company cast a for/against vote).

The 60 asset managers below cast 99.9% of the shares they voted on this item FOR (30,553,087 for, 16,664 against).

FOR 99.9%

FOR: 30,553,087 (99.9%)AGAINST: 16,664 (0.1%)

Largest asset managers voting on “TO APPROVE THE VIRIDIAN THERAPEUTICS, INC. 2025 EMPLOYEE STOCK PURCHASE PLAN.” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	12,261,049	0	For
Vanguard	4,462,994	0	For
Kynam Capital Management, LP	3,477,428	0	For
BlackRock	1,711,951	0	For
T. Rowe Price	1,575,728	0	For
AllianceBernstein	1,058,977	0	For
State Street	893,698	0	For
Loomis Sayles	784,032	0	For
Charles Schwab	581,864	0	For
Victory Capital	500,814	0	For
Yiheng Capital Management, L.P.	278,786	0	For
Bridge Builder Trust	272,951	0	For
Brighthouse	236,350	16,664	For
Brinker Capital Destinations Trust	230,461	0	For
Principal	212,669	0	For
Equitable	202,380	0	For
DRIEHAUS MUTUAL FUNDS	185,549	0	For
TIAA	182,918	0	For
JPMorgan	170,552	0	For
OPTIMUM FUND TRUST	131,578	0	For
QUANTITATIVE MASTER SERIES LLC	128,358	0	For
American Century	122,726	0	For
CARILLON SERIES TRUST	88,326	0	For
AIG/SunAmerica	78,390	0	For
Russell Investments	76,504	0	For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

4. To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Chris Cain, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 68,841,891WITHHELD: 3,200,341

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Chris Cain, Ph.D.”): 68,841,891 for, 3,200,341 withheld, per its Form 8-K filed 2025-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,589,427 outstanding shares: 84% for, 4% withheld (88% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (25,365,856 for, 0 against).

FOR 94%

FOR: 25,365,856 (93.6%)ABSTAIN: 1,722,863 (6.4%)

Largest asset managers voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	12,261,049	0	For
Vanguard	4,462,994	0	For
BlackRock	1,711,951	0	For
T. Rowe Price	1,575,728	0	For
AllianceBernstein	1,058,977	0	For
State Street	893,230	468	For
Loomis Sayles	0	784,032	Abstain
Charles Schwab	0	581,864	Abstain
Victory Capital	500,814	0	For
Yiheng Capital Management, L.P.	278,786	0	For
Bridge Builder Trust	272,951	0	For
Brighthouse	93,006	160,008	Abstain
Brinker Capital Destinations Trust	230,461	0	For
Principal	212,669	0	For
Equitable	202,380	0	For
DRIEHAUS MUTUAL FUNDS	185,549	0	For
TIAA	182,918	0	For
JPMorgan	170,552	0	For
OPTIMUM FUND TRUST	131,578	0	For
QUANTITATIVE MASTER SERIES LLC	128,358	0	For
American Century	122,726	0	For
CARILLON SERIES TRUST	88,326	0	For
AIG/SunAmerica	78,390	0	For
Russell Investments	0	76,504	Abstain
ALPS ETF Trust	61,478	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

5. To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Jeff Ajer

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 71,946,644WITHHELD: 95,588

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeff Ajer”): 71,946,644 for, 95,588 withheld, per its Form 8-K filed 2025-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,589,427 outstanding shares: 88% for, 0.2% withheld (88% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (27,072,055 for, 0 against).

FOR 99.9%

FOR: 27,072,055 (99.9%)ABSTAIN: 16,664 (0.1%)

Largest asset managers voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	12,261,049	0	For
Vanguard	4,462,994	0	For
BlackRock	1,711,951	0	For
T. Rowe Price	1,575,728	0	For
AllianceBernstein	1,058,977	0	For
State Street	893,698	0	For
Loomis Sayles	784,032	0	For
Charles Schwab	581,864	0	For
Victory Capital	500,814	0	For
Yiheng Capital Management, L.P.	278,786	0	For
Bridge Builder Trust	272,951	0	For
Brighthouse	236,350	16,664	For
Brinker Capital Destinations Trust	230,461	0	For
Principal	212,669	0	For
Equitable	202,380	0	For
DRIEHAUS MUTUAL FUNDS	185,549	0	For
TIAA	182,918	0	For
JPMorgan	170,552	0	For
OPTIMUM FUND TRUST	131,578	0	For
QUANTITATIVE MASTER SERIES LLC	128,358	0	For
American Century	122,726	0	For
CARILLON SERIES TRUST	88,326	0	For
AIG/SunAmerica	78,390	0	For
Russell Investments	76,504	0	For
ALPS ETF Trust	61,478	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

6. To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Sarah Gheuens, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 55,346,802WITHHELD: 16,695,430

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sarah Gheuens, M.D., Ph.D.”): 55,346,802 for, 16,695,430 withheld, per its Form 8-K filed 2025-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,589,427 outstanding shares: 68% for, 20% withheld (88% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (24,201,813 for, 0 against).

FOR 89%11%

FOR: 24,201,813 (89.3%)ABSTAIN: 2,886,906 (10.7%)

Largest asset managers voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	12,261,049	0	For
Vanguard	4,462,994	0	For
BlackRock	1,711,951	0	For
T. Rowe Price	1,575,728	0	For
AllianceBernstein	1,058,977	0	For
State Street	2,547	891,151	Abstain
Loomis Sayles	784,032	0	For
Charles Schwab	581,864	0	For
Victory Capital	0	500,814	Abstain
Yiheng Capital Management, L.P.	278,786	0	For
Bridge Builder Trust	19,621	253,330	Abstain
Brighthouse	211,411	41,603	For
Brinker Capital Destinations Trust	0	230,461	Abstain
Principal	212,669	0	For
Equitable	202,380	0	For
DRIEHAUS MUTUAL FUNDS	0	185,549	Abstain
TIAA	182,918	0	For
JPMorgan	170,552	0	For
OPTIMUM FUND TRUST	0	131,578	Abstain
QUANTITATIVE MASTER SERIES LLC	128,358	0	For
American Century	0	122,726	Abstain
CARILLON SERIES TRUST	0	88,326	Abstain
AIG/SunAmerica	0	78,390	Abstain
Russell Investments	76,504	0	For
ALPS ETF Trust	0	61,478	Abstain

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

7. TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 76,059,006AGAINST: 577,139

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:”): 76,059,006 for, 577,139 against, per its Form 8-K filed 2025-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,589,427 outstanding shares: 93% for, 0.8% against (94% of the company cast a for/against vote).

The 59 asset managers below cast 99.9% of the shares they voted on this item FOR (27,072,003 for, 52 against).

FOR 99.9%

FOR: 27,072,003 (99.9%)AGAINST: 52 (0.0%)ABSTAIN: 16,664 (0.1%)

Largest asset managers voting on “TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEA” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Fidelity	12,261,049	0	0	For
Vanguard	4,462,994	0	0	For
BlackRock	1,711,951	0	0	For
T. Rowe Price	1,575,728	0	0	For
AllianceBernstein	1,058,977	0	0	For
State Street	893,646	52	0	For
Loomis Sayles	784,032	0	0	For
Charles Schwab	581,864	0	0	For
Victory Capital	500,814	0	0	For
Yiheng Capital Management, L.P.	278,786	0	0	For
Bridge Builder Trust	272,951	0	0	For
Brighthouse	236,350	0	16,664	For
Brinker Capital Destinations Trust	230,461	0	0	For
Principal	212,669	0	0	For
Equitable	202,380	0	0	For
DRIEHAUS MUTUAL FUNDS	185,549	0	0	For
TIAA	182,918	0	0	For
JPMorgan	170,552	0	0	For
OPTIMUM FUND TRUST	131,578	0	0	For
QUANTITATIVE MASTER SERIES LLC	128,358	0	0	For
American Century	122,726	0	0	For
CARILLON SERIES TRUST	88,326	0	0	For
AIG/SunAmerica	78,390	0	0	For
Russell Investments	76,504	0	0	For
ALPS ETF Trust	61,478	0	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

8. Amend Omnibus Stock Plan

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

50.2% Majority: yes · of votes cast

FOR 50.2%AGAINST 49.8%

FOR: 35,322,725AGAINST: 35,076,902

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 56 against).

ABSTAIN 99.9%

AGAINST: 56 (0.0%)ABSTAIN: 1,586,421 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Eversept Partners, LP	0	0	1,586,421	0	Abstain
UNIFIED SERIES TRUST	0	56	0	0	Against

9. Approve Qualified Employee Stock Purchase Plan

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,586,477 for, 0 against).

FOR: 1,586,477 (100.0%)

Largest asset managers voting on “Approve Qualified Employee Stock Purchase Plan” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Eversept Partners, LP	1,586,421	0	0	0	For
UNIFIED SERIES TRUST	56	0	0	0	For

Largest VIRIDIAN THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of VIRIDIAN THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 81,589,427 shares outstanding at the time of that meeting.

Top VIRIDIAN THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	29.74%
2	Commodore Capital LP	6.43%
3	Vanguard	5.69%
4	VR Adviser, LLC	4.76%
5	BlackRock	4.57%
6	T. Rowe Price	4.50%
7	Kynam Capital Management, LP	4.26%
8	Fairmount Funds Management LLC	4.22%
9	State Street	3.91%
10	AllianceBernstein	3.41%

Reported VIRIDIAN THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

VIRIDIAN THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Fairmount Funds Management LLC	21.08%	13D
Entities affiliated with Fairmount Funds Management LLC	19.07%	DEF14A
FMR (Fidelity)	14.98%	13F
Entities affiliated with FMR LLC	9.35%	DEF14A
Bellevue Group AG	8.24%	13G
BlackRock	7.00%	13F
Paradigm BioCapital Advisors LP	6.91%	13G
Deep Track Capital, LP	6.64%	13G
Entities affiliated with Deep Track Capital, LP	6.59%	DEF14A
Vanguard Group	5.59%	13F

Percentages above are of 81,589,427 shares outstanding, as reported by VIRIDIAN THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIRIDIAN THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At VIRIDIAN THERAPEUTICS INC.'s shareholder meeting held 2025-06-20, in the 2024-2025 proxy season, 199 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,561 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 78% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VIRIDIAN THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-24.

VIRIDIAN THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.